Sub-Saharan Africa faces a major public-health challenge from non-communicable diseases. Although infectious diseases continue to afflict Africa, the proportion of the overall disease burden in sub-Saharan Africa attributable to cancer is rising, and the region is predicted to have a greater than 85...% increase in cancer burden by 2030. This Series of seven papers focuses on cancer control in Africa, outlining the current situation, detailing barriers to care, and presenting ideas to advance cancer care and control in the region.
more
The Programme identifies the essential services to be provided by the health, social services, police and justice sectors as well as guidelines for the coordination of essential services and the governance of coordination processes and mechanisms. Service delivery guidelines for the core elements of... each essential service have been identified to ensure the delivery of high-quality services, particularly for low- and middle-income countries, for women and girls experiencing violence. Taken together, these elements comprise the “Essential services package”.
The package comprises seven modules. Available in different languages
more
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
Treatment of second-stage gambiense human African trypanosomiasis relied on toxicarsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine,initially in monotherapy and more recently in combination with nifurtimox (NECT), has drasticallyimproved the pro...gnosis of treated patients. However, NECT logistic and nursing requirementsremain obstacles to its deployment and use in peripheral health structures in rural sub-SaharanAfrica. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development.The main scope of this article is to discuss the potential impact of new oral therapies to improvediagnosis-treatment algorithms and patients’access to treatment, and to contribute to reach theobjectives of the recently launched gambiense humanAfrican trypanosomiasis elimination program
more
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...ed with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa.
more
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv...oir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against Trypanosoma brucei spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.
more
The control and elimination of schistosomiasis have over the last two decades involved several strategies, with the current strategy by the World Health Organization (WHO) focusing mainly on treatment with praziquantel during mass drug administration (MDA). However, the disease context is complex wi...th an interplay of social, economic, political, and cultural factors that may affect achieving the goals of the Neglected Tropical Disease (NTD) 2021-2030 Roadmap. There is a need to revisit the current top-down and reactive approach to schistosomiasis control among sub-Saharan African countries and advocate for a dynamic and diversified approach.
more
The Country Cooperation Strategy (CCS) is a medium-term strategic framework for cooperation between WHO and countries and outlines a shared agenda with priority areas of work for five years. The aim of this CSS is to define medium term vision for
WHO technical cooperation with the State of Eritrea ...for a 5-year period, 2023-2027, in support of the country’s Health Sector Strategic and Development Plan III (HSSDPIII) 2022-2026 aimed at improving the health status of its people
more
The burden of asthma in Africa is high, and yet the disease is not universally prioritised. Data on allergic asthma and its impact on asthma morbidity are limited in Africa. Our aim was to describe the distribution of skin prick positivity among asthmatics in Eastern Africa.
این مجموعه ویژه شامل مرورهای کاکرین در موضوعات زیر است: دارو، پشتیبانی رفتاری، و ترک تدریجی. مداخلاتی که عمل سیگار کشیدن را تقلید میکنند، بهویژه سیگارهای الکترون...یکی، بهعلت اینکه خطر مرتبط با استفاده از آنها در همهگیری اخیر واضح نیست؛ از این مجموعه خارج شدهاند. گروه اعتیاد به دخانیات کاکرین در حال کار هستند تا همه اطلاعات مرتبط را به منظور ارائه پشتیبانی به افرادی که در این زمان سخت در تلاش برای ترک سیگار هستند؛ بهروز نگهدارند.
more
إرشاداتٌ حول إنشاء عنابر العزل الخاصة بالحالات المصابة بفيروس كورونا المستجد
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centres and is meant to be accessible to healthcare work...ers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 isolation centre either within an existing facility or as a standalone centre.
more
The COVID-19 pandemic affects older people disproportionately, especially those living in long-term care facilities (LTCF) with significant impact on mortality and morbidity. Concerted action is needed to mitigate the impact of COVID-19 by enhancing infection prevention and control (IPC) measures wi...thin LTCF. The COVID-19 IPC course for LTCF consists of 4 training modules to be used in conjunction with the LTCF communication toolkit and preparedness checklist. This package is tailored for LTCF and based on WHO's in-depth technical guidance on IPC.
This course is also available in the following languages: Bahasa Indonesia - Nederlans
more
The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the objectives of COVID-19 vaccination programmes and links t...hose to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.
This document it available in Arabic, Chinese and Russian
more
فيما يسمى بـ "الرسائل الإخبارية"، يقوم فريق ميدبوكس بجمع الوثائق والمعلومات المتعلقة بـ كوفيد -19 في شكل مرئي. نرحب بتعليقاتكم حول التنسيق والمحتوى، بالإضافة إلى مزي... من الاقتراحات
لتحسينها وتوسيعها
more
The mhGAP Humanitarian Intervention Guide (mhGAP-HIG) Training of Health-Care Providers manual is designed to guide facilitators in training non-specialist health care providers to manage mental, neurological and substance use conditions in humanitarian emergency settings.
The manual covers sugge...sted training schedules, learning objectives, and tips for planning and facilitating the training. It also includes step-by-step training modules for different conditions covered in the mhGAP Humanitarian Intervention Guide (mhGAP-HIG).
more